Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry Eskens, George Blumenschein, Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Carol Peña, Klaus Mross

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)'. Together they form a unique fingerprint.

Medicine & Life Sciences